abiraterone acetate + glucocorticoid

Abiraterone acetate + glucocorticoid is a **combination therapy** used primarily for metastatic castration-resistant prostate cancer. Abiraterone acetate is a prodrug of **abiraterone**, a selective and irreversible inhibitor of the enzyme CYP17A1 (cytochrome P450 17α-hydroxylase/17,20-lyase), which blocks **androgen biosynthesis** required for prostate cancer growth[2][3]. However, CYP17A1 inhibition also reduces cortisol synthesis, resulting in compensatory increase in adrenocorticotropic hormone (ACTH), and accumulation of mineralocorticoid precursors that can cause hypertension, hypokalemia, and fluid retention[2][3][1]. A **glucocorticoid** (commonly prednisone or dexamethasone) is co-administered as replacement therapy, suppressing ACTH and reducing these mineralocorticoid-related toxicities; it may also modestly improve symptoms/efficacy[1][2][3]. The FDA-approved regimen is abiraterone acetate 1000 mg daily plus prednisone 5 mg twice daily[5].

Other names

abiraterone acetate + prednisoneabiraterone acetate + dexamethasone